
Join to view full profile
450 Brookline AveBoston, MA 02215
Phone+1 617-632-3468
Dr. Kehl is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2014 - 2017
Mass General Brigham/Brigham and Women's HospitalResidency, Internal Medicine, 2008 - 2011
Northwestern University The Feinberg School of MedicineClass of 2008
Certifications & Licensure
MA State Medical License 2012 - 2028
NH State Medical License 2024 - 2024
TX State Medical License 2014 - 2019
IL State Medical License 2010 - 2014
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Rule-Based Identification of a Reliable Real-World Cancer Recurrence Endpoint.Jessica A Lavery, Samantha Brown, Chelsea Nichols, Joshua S Jolissaint, Yufei Deng
Cancer Epidemiology, Biomarkers & Prevention. 2026-08-17 - Strategies for Deploying Large Language Models for Ascertaining Clinical Outcomes and Sites of Metastases From Radiology Impressions in Patients With Cancer.Syed Arsalan Ahmed Naqvi, Irbaz Bin Riaz, Amir Saeidi, Mihir Parmar, Atul Jain
JCO Clinical Cancer Informatics. 2026-07-23 - Presenting features and outcomes to standard systemic therapies in patients with MTAP-deleted advanced non-small cell lung cancer.Julian Huang, Mihaela Aldea, Kathryn W Miller, Julia K Rotow, Emanuele Mazzola
Clinical Cancer Research. 2026-07-06
Press Mentions
Grand Rounds August 1, 2025: Clinical Trial Notifications Triggered by Artificial Intelligence-Detected Cancer Progression (Kenneth L. Kehl, MD, MPH)August 1st, 2025
Biomarker Testing in Advanced Cancer Still Lags Behind Guideline RecommendationsJuly 11th, 2025
Harnessing AI and Genomics in Clinical Trial EnrollmentJune 26th, 2025
Grant Support
- ACTIVATE: AI-driven Clinical Trial Information and Viability Assessment Tool for EHRsDANA-FARBER CANCER INST2025–2030
- Deep clinical trajectory modeling to optimize accrual to cancer clinical trialsDANA-FARBER CANCER INST2020–2025
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:









